MA28778B1 - Compositions de risedronate et procede d'utilisation de celle-ci - Google Patents
Compositions de risedronate et procede d'utilisation de celle-ciInfo
- Publication number
- MA28778B1 MA28778B1 MA29645A MA29645A MA28778B1 MA 28778 B1 MA28778 B1 MA 28778B1 MA 29645 A MA29645 A MA 29645A MA 29645 A MA29645 A MA 29645A MA 28778 B1 MA28778 B1 MA 28778B1
- Authority
- MA
- Morocco
- Prior art keywords
- risedronate
- compositions
- polymorph
- solvate
- orally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Cette invention a pour objet un procédé comprenant l'administration par voie orale, à un être humain ou à un autre mammifère, d'une composition pharmaceutique comprenant entre environ 65 % et environ 110 % de la dose efficace accumulée de risédronate ou d'un acide, d'un sel, d'un ester, d'un solvate ou d'un polymorphe de qualité pharmaceutique, suivant un programme de dosage en continu sur un, deux ou trois jours consécutifs par mois, utile pour le traitement ou la prévention de l'ostéoporose et des autres troubles métaboliques osseux.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/897,897 US20050070504A1 (en) | 2001-12-21 | 2004-07-23 | Risedronate compositions and their methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28778B1 true MA28778B1 (fr) | 2007-08-01 |
Family
ID=34958880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29645A MA28778B1 (fr) | 2004-07-23 | 2007-02-01 | Compositions de risedronate et procede d'utilisation de celle-ci |
Country Status (20)
Country | Link |
---|---|
US (1) | US20050070504A1 (fr) |
EP (1) | EP1776123A1 (fr) |
JP (3) | JP5377852B2 (fr) |
KR (2) | KR20070038115A (fr) |
CN (1) | CN101146542A (fr) |
AR (1) | AR046036A1 (fr) |
AU (2) | AU2004322703B2 (fr) |
BR (1) | BRPI0418973A (fr) |
CA (1) | CA2564898A1 (fr) |
IL (1) | IL180907A0 (fr) |
IS (1) | IS8597A (fr) |
MA (1) | MA28778B1 (fr) |
MX (1) | MX2007000967A (fr) |
NO (1) | NO20071058L (fr) |
NZ (1) | NZ552799A (fr) |
PE (1) | PE20060144A1 (fr) |
RU (1) | RU2007103306A (fr) |
TW (1) | TWI351286B (fr) |
WO (1) | WO2006022755A1 (fr) |
ZA (1) | ZA200701308B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL371264A1 (en) * | 2001-12-21 | 2005-06-13 | The Procter & Gamble Company | Method for the treatment of bone disorders |
ES2532393T3 (es) * | 2002-05-10 | 2015-03-26 | F. Hoffmann-La Roche Ag | Acidos bisfosfónicos para tratamiento y prevención de osteoporosis |
DE60315514T3 (de) * | 2002-12-20 | 2012-04-26 | F. Hoffmann-La Roche Ag | Hochdosierte ibandronat-formulierung |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
AU2011218625B2 (en) * | 2004-05-24 | 2014-03-20 | Theramex HQ UK Limited | Dosage forms of risedronate |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
US7473684B2 (en) * | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
US20070122477A1 (en) * | 2005-10-12 | 2007-05-31 | Cytochroma, Inc. | Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
KR100844256B1 (ko) | 2007-03-23 | 2008-07-07 | 코오롱제약주식회사 | 리세드로네이트와 비타민 d를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법 |
JP2011529901A (ja) * | 2008-07-31 | 2011-12-15 | 味の素株式会社 | リセドロネートまたはその塩の低投与量形態 |
KR101379664B1 (ko) * | 2008-09-23 | 2014-04-02 | 한림제약(주) | 리세드론산 또는 그의 염 및 비타민 d를 포함하는 약학 조성물 |
KR101102364B1 (ko) | 2009-09-18 | 2012-01-03 | 한림제약(주) | 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물 |
PT106978A (pt) * | 2013-05-31 | 2014-12-02 | Tecnimede Sociedade Tecnico Medicinal S A | Composição sólida oral contendo ácido ibandrónico e vitamina d |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA777769A (en) * | 1963-03-18 | 1968-02-06 | H. Roy Clarence | Substituted methylene diphosphonic acid compounds and detergent compositions |
IT1201087B (it) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
FR2531088B1 (fr) * | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
US4761406A (en) * | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
DE3623397A1 (de) * | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
CA1339805C (fr) * | 1988-01-20 | 1998-04-07 | Yasuo Isomura | Acide (cycloalkylamino) methylenebis phosphonique et medicaments le contenant comme ingredients actif |
GB2217988B (en) * | 1988-04-11 | 1992-04-01 | Gould Leonard W | Regimen for increasing bone density in humans |
US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
US5227506A (en) * | 1989-09-06 | 1993-07-13 | Merck & Co., Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
NL8902727A (nl) * | 1989-11-06 | 1991-06-03 | Philips Nv | Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem. |
AU675796B2 (en) * | 1992-06-30 | 1997-02-20 | Procter & Gamble Pharmaceuticals, Inc. | Compositions for the treatment of arthritis containing phosphonates and NSAIDS |
US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
US6008206A (en) * | 1994-09-21 | 1999-12-28 | Merck & Co., Inc. | Sodium alendronate preparation for local administration |
US6750216B2 (en) * | 1996-03-08 | 2004-06-15 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
US5730715A (en) * | 1996-06-14 | 1998-03-24 | Becton Dickinson And Company | Method for the iontophoretic administration of bisphosphonates |
GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
HUP0004625A1 (hu) * | 1997-06-11 | 2001-06-28 | The Procter & Gamble Co. | Az emésztőcsatorna felső szakaszának fokozott biztonságot nyújtó filmbevonatos tabletta |
US6432932B1 (en) * | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US5994329A (en) * | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US6331533B1 (en) * | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
US6225801B1 (en) * | 1999-01-14 | 2001-05-01 | Lucent Technologies Inc. | Article comprising electronic circuits and devices with magnetically programmable electrical resistance |
JP2001253827A (ja) * | 2000-02-15 | 2001-09-18 | Pfizer Prod Inc | 骨粗鬆症を治療するための組成物および方法 |
US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
CN1272013C (zh) * | 2000-06-20 | 2006-08-30 | 诺瓦提斯公司 | 二膦酸盐在制备用于治疗骨更新异常增加的病症的药物中的应用 |
US6593310B1 (en) * | 2000-11-21 | 2003-07-15 | Arthropharm Pty. Ltd. | Treatment of osteoporosis |
JP2005516928A (ja) * | 2001-12-13 | 2005-06-09 | メルク エンド カムパニー インコーポレーテッド | 骨異常のためのビスホスホネート液体製剤 |
ES2532393T3 (es) * | 2002-05-10 | 2015-03-26 | F. Hoffmann-La Roche Ag | Acidos bisfosfónicos para tratamiento y prevención de osteoporosis |
US20040188316A1 (en) * | 2003-03-26 | 2004-09-30 | The Procter & Gamble Company | Kit for pharmaceutical use |
-
2004
- 2004-07-23 US US10/897,897 patent/US20050070504A1/en not_active Abandoned
- 2004-09-25 MX MX2007000967A patent/MX2007000967A/es unknown
- 2004-09-25 KR KR1020077001602A patent/KR20070038115A/ko not_active Application Discontinuation
- 2004-09-25 AU AU2004322703A patent/AU2004322703B2/en not_active Withdrawn - After Issue
- 2004-09-25 CN CNA2004800436570A patent/CN101146542A/zh active Pending
- 2004-09-25 WO PCT/US2004/031975 patent/WO2006022755A1/fr active Application Filing
- 2004-09-25 CA CA002564898A patent/CA2564898A1/fr not_active Abandoned
- 2004-09-25 BR BRPI0418973-6A patent/BRPI0418973A/pt not_active Application Discontinuation
- 2004-09-25 JP JP2007522476A patent/JP5377852B2/ja active Active
- 2004-09-25 RU RU2007103306/14A patent/RU2007103306A/ru unknown
- 2004-09-25 KR KR1020087021196A patent/KR20080083219A/ko active Search and Examination
- 2004-09-25 NZ NZ552799A patent/NZ552799A/en not_active IP Right Cessation
- 2004-09-25 EP EP04789250A patent/EP1776123A1/fr not_active Ceased
- 2004-09-29 AR ARP040103537A patent/AR046036A1/es unknown
- 2004-09-30 PE PE2004000960A patent/PE20060144A1/es not_active Application Discontinuation
- 2004-11-30 TW TW093136901A patent/TWI351286B/zh not_active IP Right Cessation
-
2007
- 2007-01-23 IL IL180907A patent/IL180907A0/en unknown
- 2007-01-24 IS IS8597A patent/IS8597A/is unknown
- 2007-02-01 MA MA29645A patent/MA28778B1/fr unknown
- 2007-02-14 ZA ZA200701308A patent/ZA200701308B/en unknown
- 2007-02-22 NO NO20071058A patent/NO20071058L/no not_active Application Discontinuation
-
2011
- 2011-03-02 AU AU2011200905A patent/AU2011200905A1/en not_active Abandoned
-
2013
- 2013-08-16 JP JP2013169220A patent/JP5761274B2/ja active Active
-
2014
- 2014-10-21 JP JP2014214604A patent/JP5910698B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
AU2004322703A1 (en) | 2006-03-02 |
ZA200701308B (en) | 2008-07-30 |
NO20071058L (no) | 2007-02-22 |
CN101146542A (zh) | 2008-03-19 |
AU2004322703B2 (en) | 2010-12-02 |
JP5910698B2 (ja) | 2016-04-27 |
TW200603816A (en) | 2006-02-01 |
MX2007000967A (es) | 2007-07-11 |
JP2015038135A (ja) | 2015-02-26 |
CA2564898A1 (fr) | 2006-03-02 |
NZ552799A (en) | 2010-04-30 |
IS8597A (is) | 2007-01-24 |
JP5761274B2 (ja) | 2015-08-12 |
TWI351286B (en) | 2011-11-01 |
IL180907A0 (en) | 2007-07-04 |
AU2011200905A1 (en) | 2011-03-24 |
US20050070504A1 (en) | 2005-03-31 |
WO2006022755A1 (fr) | 2006-03-02 |
EP1776123A1 (fr) | 2007-04-25 |
JP2013231087A (ja) | 2013-11-14 |
JP2008507513A (ja) | 2008-03-13 |
JP5377852B2 (ja) | 2013-12-25 |
AR046036A1 (es) | 2005-11-23 |
KR20080083219A (ko) | 2008-09-16 |
PE20060144A1 (es) | 2006-04-17 |
BRPI0418973A (pt) | 2007-12-04 |
RU2007103306A (ru) | 2008-09-10 |
KR20070038115A (ko) | 2007-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28778B1 (fr) | Compositions de risedronate et procede d'utilisation de celle-ci | |
RU2018133298A (ru) | Способы применения агонистов fxr | |
TW200744673A (en) | Improved ibandronate formulations | |
MA34474B1 (fr) | Agonistes de gpr40 | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
IS8807A (is) | Notkun á daptómýsíni og lyfjasamsetningar sem innihalda það | |
RS54187B1 (en) | PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE CONTAINING FUMARIC ACID ESTAR | |
TNSN07482A1 (fr) | Nouvelles compositions injectables et procede de preparation desdites compositions | |
TNSN99223A1 (fr) | Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et procedes de traitement les utilisant | |
RU95102778A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен | |
ES2165969T3 (es) | Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios. | |
BR0008060A (pt) | Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica | |
JP2015038135A5 (fr) | ||
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
ES2168471T3 (es) | 2-(5h)-furanonas diaril-5-oxigenadas como inhibidores de la cox-2. | |
MA37850A1 (fr) | Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale | |
MA35513B1 (fr) | Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine | |
EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
HUP0400645A2 (hu) | NMDA-receptor agonistát tartalmazó gyógyászati készítmények | |
MA30413B1 (fr) | Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation | |
TNSN04045A1 (fr) | Compositions de valdecoxib a delitement intra-oral | |
MA52154B1 (fr) | Composition pharmaceutique pour l'anémie | |
AU2001277904B2 (en) | Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses | |
Gatti et al. | Clinical development of neridronate: potential for new applications | |
HK1087039A1 (en) | Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass |